吉西他滨联合顺铂治疗晚期食管癌的临床观察

The Clinical Observation of Gemcitabine and Cisplatin in the Treatment of Patients with Advanced Esophageal Cancer

目的观察吉西他滨联合顺铂一线治疗晚期食管癌的临床疗效及毒副反应。方法 33例无法手术治疗的局部晚期食管癌患者接受吉西他滨联合顺铂方案:吉西他滨1 000 mg.m-2,d1,8,静脉滴注;顺铂30 mg.m-2,d2～4,静脉滴注,21 d为1周期,所有患者均接受不少于2周期的化疗。治疗结束后评价疗效和毒副反应。结果 33均可评价疗效,其中CR 1例,PR 16例,SD 10例,PD 6例,总有效率为51.5%,临床获益率为81.8%,毒副反应主要是骨髓抑制和消化道反应,治疗有效的患者进食困难和胸痛均不同程度缓解。结论吉西他滨联合顺铂一线治疗晚期食管癌可获得较好的疗效,且毒副反应可耐受。

Objective To investigate the efficacy and toxicities of gemcitabine plus cisplatin in the treatment of advanced esophageal cancer. Methods All the 33 patients with advanced esophageal cancer received the gemcitabine plus cisplatin treatment： gemcitabine 1 000 mg · m-2, d1 .8, intravenous infusion; cisplatin 80 mg· m-2, d2.4, intravenous infusion ; 21 days were one cycle. The efficacy and toxicities were observed. Results Among the 33 pa- tients, C R in the 1 patient, PR in the 16 patients, SD in the 10 patients, PD in the 6 patients,the total effective rate was 51.5% ,the clinical benefit rate was 81.8%. The main toxicities were myelosuppression and gastrointestinal re- action, eating difficulties and chest pain were alleviated in the patients who obtained the effective treatment. Conclu- sion Gemcitabine plus cisplatin as the first line treatment regimen can get good efficacy in the treatment of advanced esoDhazeal cancer, and the toxicities can be tolerated.